KATIE ROWLAND: Open Payments
NPI 1366180564 · CONNERSVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$723 in 46 payments from 11 companies in 2025. Trend: 2023 $388 · 2024 $918 · 2025 $723
Food & beverage: $628Education: $95
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 17 | $212 |
| ABBVIE INC. | 12 | $202 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $68 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| PFIZER INC. | 2 | $42 |
| Lundbeck LLC | 2 | $35 |
| Novo Nordisk Inc | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Neurocrine BioSciences, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
Products named: FANAPT, VRAYLAR, REXULTI, CAPLYTA, QULIPTA, Ozempic, ELIQUIS, Auvelity.
Industry payments across IN — which companies pay providers there.
